Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
08/11/2023 | Press release | Distributed by Public on 08/11/2023 11:56
Please select the service you want to use:
Smartlinks | Wynn Resorts Limited | Finance | Security Markets | Security Markets | Company News | Investment Funds | Arts and Culture | Entertainment | Casino and Gambling | Travel, Leisure and Recreation Industry | Securities Issuers | Casino Operating Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | Bolsa Institucional de Valores (BIVA) | Hannover Stock Exchange | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact